In this 8-week randomised , double-blind , parallel-group trial , patients were randomized to receive either extrafine BDP/FF NEXThaler ( ) 100/6g bid , extrafine BDP/FF 100/6g pMDI bid or non-extrafine BDP DPI 100g bid .